Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept biosimilar - Prestige Biopharma

Next Previous
Drug Profile

Aflibercept biosimilar - Prestige Biopharma

Alternative Names: PBP 1602

Latest Information Update: 30 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prestige BioPharma
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Retinal disorders; Retinal oedema
  • Discontinued Colorectal cancer

Most Recent Events

  • 24 Jul 2024 Discontinued - Phase-I for Colorectal cancer (Metastatic disease) in Singapore (Parenteral) before July 2024 (Prestige BioPharma pipeline, July 2024)
  • 24 Jul 2024 Aflibercept biosimilar is still in preclinical trials for Retinal disorders and Retinal oedema in Singapore (Prestige BioPharma pipeline, July 2024)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Colorectal-cancer(Metastatic disease) in Singapore (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top